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Introduction
Dyspareunia, literally “bad or difficult mating”, is
sexual dysfunction manifested as painful or difficult
sexual intercourse.1 In women, it is generally defined
as genital pain occurring with penetration or during or
after intercourse but not exclusively vaginismus (a
common type of insertional dyspareunia caused by
intense involuntary contraction of the perineal muscles
surrounding the outer one third of the vagina).2 A
condition rare in men, dyspareunia affects an estimated
10–15% of sexually active women.3 The etiologic
theorizing has also been mostly dualistic, with
gynecology focusing on cases associated with observable
peripheral pathology and psychiatry/psychology
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focusing on cases where no such pathology was evident.
Dyspareunia is classified by onset (primary versus
secondary), frequency (complete versus situational),
and location of pain (insertional versus deep).4
Deep dyspareunia, often described as deep pelvic
pain resulting from deep penile thrusting during
sexual intercourse, is also common and has many causes.
Major causes include pelvic inflammatory disease;
gynecologic, pelvic, or abdominal surgery; postoperative
adhesions; endometriosis; genital or pelvic tumors;
irritable bowel syndrome; urinary tract infections; and
ovarian cysts. Also a common cause is positional, with
deep thrusting by the woman’s partner hitting an ovary
(equivalent to hitting or squeezing a man’s testicle).5 A
diagnosis integrating medical and psychosexual factors
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is the first step in the effective treatment of dyspareunia,
a condition requiring physiopathologically oriented
treatment of the organic factors and therapy related
to the individual’s and couple’s psychosexual issues.6
So far, there have been very few articles mentioned
about the specific treatment for deep dyspareunia.
The 2 procedures that have been documented for the
treatment of deep dyspareunia were laparoscopic
uterosacral ligament ablation (LUNA) and uterine
ventrosuspension. As described in Vercellini et al’s
article,7 LUNA was originally performed to treat
dysmenorrhea associated with endometriosis, and
accidentally LUNA was found to have efficacy for
deep dyspareunia.8
In this pilot study, we sought to investigate the role
of LUNA in the treatment of deep dyspareunia.
Methods
This prospective pilot study was undertaken between
July 2002 and June 2003 to evaluate the efficacy of
LUNA for the treatment of primary deep dyspareunia.
Consecutive patients with clinical evidence of primary
deep dyspareunia were included upon giving informed
consent. LUNA, with a therapeutic intent, was
performed to cauterize the bilateral uterosacral ligament
using an electric bipolar instrument (Valleylab, CO,
USA). The optimal site of coagulation of the sensory
nerves in the uterosacral ligament was chosen according
to Fujii et al.9 To prevent the potential side effect of
uterine prolapse, we decided to coagulate the
uterosacral ligament only, instead of transecting it.10
Patients with a previous clinical or endoscopic diagnosis
of endometriosis or with other diseases that might
cause deep dyspareunia (such as chronic pelvic
inflammatory disease, pelvic varices, or genital
malformations) were excluded. Other exclusion criteria
were the presence of a congenital vaginal anomaly;
existence of pelvic congestion; previous diagnosis of
gastrointestinal, urologic, and orthopedic diseases in
which pain may radiate to the pelvic area; and known
psychiatric disturbances.
During the study period, 12 patients complaining
of deep dyspareunia were prospectively evaluated by
adherence to a strict protocol that consisted of pelvic
examination, ultrasonography, and questionnaires to
determine psychologic status and sexual functioning.
Pelvic symptoms and physical findings were assessed at
each follow-up visit by 1 senior physician (H.C.H.) on
a modification of a published scale.11
After the LUNA procedure, patients underwent
clinical evaluation at months 3, 6, and 12. Patients
were withdrawn from the study if, after the surgery,
they used any type of hormonal therapy that could
affect pain symptoms. At baseline and each follow-up
visit, all patients were asked to complete the submitted
forms of the Hospital Anxiety and Depression Scale
(HADS)12 and the revised Sabbatsberg Sexual Rating
Scale (rSSRS).13
The HADS was originally developed for use in
hospital settings, as the name suggests. It was designed
as a self-completed questionnaire to assess patients’
anxiety and depression during inpatient care according
to 2 subscales. Both subscales comprise 7 questions,
rated from a score of 0 to 3 depending on the severity
of the problem described in each question. The 2
subscales can also be aggregated to provide an overall
anxiety and depression score. The HADS has shown to
be a reliable instrument for screening, and a valid
measure of severity of these mood disorders in patients
under investigation in medical and surgical departments.
The rSSRS is a 12-item questionnaire for the
assessment of sexual functioning. For each item, there
are 5 possible answers, scored from 0 to 4 points (from
the lowest to the highest sexual satisification). The
scores of 12 items are then summed and transformed
to a scale of 0 to 100. Scores between these values
represent the percentage of the total possible score.
The validity and reliability of this questionnaire have
been demonstrated.
The submitted HADS and rSSRS forms were
interpreted by one of the authors (M.S.Y.) blinded to
patients and treatment. At the final 12-month follow-
up evaluation, all patients were requested to rate the
overall degree of satisification with their treatment on
a 5-category Likert scale (very satisfied, satisfied,
uncertain, dissatisfied, very dissatisfied).
Statistical analysis was performed using a computer-
based statistical package (SPSS version 10.0; SPSS
Inc., Chicago, IL, USA). Variables were compared
statistically using the Friedman test or Wilcoxon test,
where appropriate. A p value of less than 0.05 was
considered to be statistically significant.
Results
By strict adherence to the protocol for diagnostic
evaluation of primary deep dyspareunia, 12 patients
were identified and enrolled into the study. Baseline
clinical characteristics and median pelvic pain, rSSRS,
and HADS scores are listed in Table 1. The mean and
standard deviation of surgical time for the LUNA
procedure was 24 ( 9 minutes. The mean age of the
study patients was 34.9 ( 5.6 years, and the mean
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parity was 1.4 ( 0.9. The median and percentile profile
for HADS score (anxiety, depression, total) and rSSRS
score of study subjects are given in Figures 1–4.
We found a significant decrease in scores over
follow-up visits, which reflected the potential role of
LUNA for the treatment of pure deep dyspareunia.
The rSSRS score showed gradual improvement in
sexual function over the follow-up period and a
statistically significant improvement was evident in
12 months.
The Likert scale showed that, at the initial 3-month
follow-up visit, 3 of the 12 study subjects were very
satisfied with their treatment, 5 were satisfied, 2
uncertain, 1 dissatisfied, and 1 very dissatisfied.
Corresponding figures at the final 12-month follow-
up visit were 2, 4, 4, 1, and 1, respectively. Overall, 8
(66.7%) of 12 patients were very satisfied or satisfied at
the initial postoperative evaluation, while 6 (50.0%)
were satisfied at the final evaluation.
At the same time, the authors also found that, at the
initial evaluation, 6 (75%) of the 8 patients who were
satisfied with LUNA also had improvement of
menstrual pain, and the results were maintained
throughout the follow-up period.
Figure 1. Box-plot diagram for Hospital Anxiety and Depression
Scale (HADS) anxiety score at baseline evaluation and serial
follow-up visits. This box contains the middle half of the scores
in the distribution. The lowest line denotes the 10th percentile
value and the highest line denotes the 90th percentile value.
*p < 0.05, as compared to baseline value, by Wilcoxon test.
Figure 2. Box-plot diagram for Hospital Anxiety and Depression
Scale (HADS) depression score at baseline evaluation and serial
follow-up visits. This box contains the middle half of the scores
in the distribution. The lowest line denotes the 10th percentile
value and the highest line denotes the 90th percentile value.
*p < 0.05, as compared to baseline value, by Wilcoxon test.
Table 1. Baseline clinical characteristics of the 12 study patients
Age, History of
Duration of Chronic Pelvic HADS HADS HADS
rSSRS
Cases
yr
Parity
dysmenorrhea
preoperative pelvic symptom anxiety depression total
score
dyspareunia, yr pain score score score score
1 28 1 + 3 + 5 5 6 11 68
2 34 0 + 6 – 7 6 8 14 74
3 30 2 – 1 – 8 5 9 14 65
4 38 1 + 2.6 + 6 8 11 19 54
5 43 1 + 4 + 8 2 7 9 65
6 37 3 + 3 + 9 7 8 15 58
7 36 2 – 5 – 6 9 17 26 73
8 45 0 + 0.7 – 7 10 12 22 57
9 30 1 + 1 + 9 6 7 13 46
10 29 1 + 2 + 5 8 8 16 22
11 39 2 + 2 – 4 11 13 24 54
12 30 3 – 6 – 5 8 14 22 18
HADS = Hospital Anxiety and Depression Scale; rSSRS = revised Sabbatsberg Sexual Rating Scale.
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No side effects attributable to pelvic denervation,
specifically changes in urinary bladder and intestinal
function, were observed. Of note, postoperatively,
only 2 patients had mild fever and 3 patients had mid-
pelvic pain that lasted less than 3 days, which resolved
spontaneously after conservative treatment. No patients
had de novo dyspareunia, and frequencies of orgasms
were not affected. Preoperatively, 7 patients needed
lubricants for assisting intercourse and only 2 patients
maintained such assistance at the final 12-month visit
(p < 0.05, by Chi-square test).
Discussion
The Lee-Frankenhauser sensory nerve plexuses and
parasympathetic ganglia in the uterosacral ligaments
carry pain from the uterus, cervix, and other pelvic
structures.14 Theoretically, interruption of these nerve
trunks by LUNA may alleviate deep dyspareunia.
However, the balance of benefits and risks of this
intervention has not been reliably assessed. LUNA
has, nevertheless, been introduced into practice,
although opinion regarding its value is not yet solidified
and there remain controversies regarding indications
for LUNA.
Dyspareunia is a symptom of multiple and verified
disease states and may have multiple causes with
components of both organic and psychiatric
dysfunction. It is classified by onset (primary versus
secondary), frequency (complete versus situational),
and location of pain (insertional versus deep). Women
suffering from dyspareunia shuttle back and forth
from mental health professionals to physicians
searching for a cure, with little empirical evidence
available as to the ways in which dyspareunic pain
may be mediated. Traditionally, it was thought that
superficial dyspareunia (at or around the vaginal
entrance) is likely to have a psychogenic origin,
whereas deep dyspareunia is likely to have an organic
cause. These explanations are no longer considered
helpful. It is important to try to identify the history
of pain; its site, sort, severity, onset, and duration; and
any other associated factors. Meana et al15 found that
the location of pain and its onset with an episode of
intercourse were the strongest predictors of presence
and type of organicity.
Treatment of dyspareunia should be directed at
underlying causes. It can be as simple as prescribing
antibiotics for vaginal infection or may involve
hormonal or surgical therapy for endometriosis.
Adjunctive therapy, such as prescription of a vaginal
lubricant or local anesthetic or institution of pelvic
relaxation exercises, may also be useful.
The original intent of LUNA was to treat the
problem of dysmenorrhea with or without
endometriosis. In the current study, we found it can
play a promising role in the treatment of primary deep
dyspareunia and that it had a comparable effectiveness
with uterine ventrosuspension, as published by Halperin
et al.8 More important, the side effects of LUNA were
negligible.
Figure 4. Box-plot diagram for revised Sabbatsberg Sexual Rating
Scale (rSSRS) score at baseline evaluation and serial follow-up
visits. This box contains the middle half of the scores in the
distribution. The lowest line denotes the 10th percentile value and
the highest line denotes the 90th percentile value. *p < 0.05, as
compared to baseline value, by Wilcoxon test.
Figure 3. Box-plot diagram for Hospital Anxiety and Depression
Scale (HADS) total score at baseline evaluation and serial follow-
up visits. This box contains the middle half of the scores in the
distribution. The lowest line denotes the 10th percentile value and
the highest line denotes the 90th percentile value. *p < 0.05, as
compared to baseline value, by Wilcoxon test.
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In conclusion, LUNA was promising for the
treatment of primary deep dyspareunia, which
potentially extended the indications of LUNA. Further
large-scale randomized controlled trials are needed to
verify its real effect.
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